Jazz Pharmaceuticals, Inc. JAZZ

Jazz Pharmaceuticals Public Limited Company es una empresa biofarmacéutica. La empresa se enfoca en desarrollar y comercializar productos que abordan necesidades médicas no satisfechas. La empresa tiene un portafolio diverso de productos y candidatos a productos con un enfoque en las áreas de sueño y hematología/oncología. Los productos principales comercializados por la empresa incluyen Xyrem (solución oral de oxibato de sodio) para el tratamiento tanto de la cataplejía como de la somnolencia diurna excesiva en pacientes con narcolepsia; Erwinaze para el tratamiento de la leucemia linfoblástica aguda (LLA), y Defitelio (defibrotida) para el tratamiento de la enfermedad veno-oclusiva hepática grave (VOD). La empresa también comercializa Prialt, una infusión intratecal de ziconotida aprobada por la FDA para el manejo del dolor crónico severo en pacientes para quienes la terapia intratecal está indicada, y que son intolerantes o refractarios a otros tratamientos, como analgésicos sistémicos, terapias adyuvantes o morfina intratecal.

• The Motley Fool 18 sept

  Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?

  Jazz Pharmaceuticals acquired Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments to gain control of ABS-1230, a potential first-in-class treatment for KCNT1-related epilepsy. The acquisition strengthens Jazz's existing epilepsy franchise, which includes the successful Epidiolex drug generating $292 million in Q2 sales. While clinical trial risks exist, Jazz's strong revenue growth (16% YoY to $1.2 billion in Q2) and solid cash generation support the investment. At 9.5x forward earnings, the stock appears reasonably valued for a profitable biotech with double-digit growth.

  

• Zacks Investment Research 2 sept

  Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?

  Jazz Pharmaceuticals missed Q2 2026 EPS expectations ($5.71 vs. $6.04 estimate) due to $77 million in acquired IPR&D expenses, but beat revenue estimates at $1.21 billion. The company raised full-year 2026 revenue guidance to $4.60-$4.75 billion, driven by strong performance in its sleep franchise (Xywav up 13%), epilepsy business (Epidiolex up 16%), and oncology portfolio (up 32%). Despite the positive outlook, shares have underperformed the S&P 500 by 6.9% since the earnings report.

  

• Zacks Investment Research 1 sept

  Axsome Begins Phase III Study on AXS-05 for Smoking Cessation

  Axsome Therapeutics has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for smoking cessation. The randomized, double-blind, placebo-controlled trial will compare AXS-05 against bupropion and placebo over 12 weeks, with smoking abstinence as the primary endpoint. Axsome's lead drug Auvelity continues to drive strong revenue growth, generating $333 million in H1 2026 (up 54.2% YoY), while the company's diversified portfolio includes Sunosi and newly launched Symbravo.

  

• Zacks Investment Research 1 sept

  JAZZ Rises on Updated OS Results From Gastric Cancer Study

  Jazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.